Table 1.
Demographic, clinical, and pathological characteristics of patients that generated the TMAs
| (N = 147) | |
|---|---|
| Age, M (Q1–Q3) | 63 (58–67) |
| Race, n (%) | |
| Non-black | 82 (56%) |
| Black | 65 (44%) |
| Year of Surgery, M (Q1-Q3) | 1998 (1994–1999) |
| PSA (ng/mL), M (Q1-Q3) | 8.9 (5.6–13.4) |
| Pathological Grade Group, n (%): | |
| 1 | 74 (50%) |
| 2–3 | 67 (46%) |
| 4–5 | 6 (4%) |
| Positive Margins, n (%) | 58 (39%) |
| Seminal vesicle invasion, n (%) | 16 (11%) |
| Extracapsular extension, n (%) | 13 (9%) |
| Positive lymph nodes, n (%) | 26 (18%) |
| Follow-up (years), M (Q1–Q3) | 7.2 (6.2–8.7) |
SD standard deviation, M median, Q1 25th percentile, Q3 75th percentile, BMI body mass index, PSA prostate specific antigen